Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

KalVista Pharmaceuticals (KALV) Return on Capital Employed (2017 - 2025)

KalVista Pharmaceuticals' Return on Capital Employed history spans 10 years, with the latest figure at 85.01% for Q2 2025.

  • On a quarterly basis, Return on Capital Employed rose 746.0% to 85.01% in Q2 2025 year-over-year; TTM through Apr 2025 was 85.01%, a 746.0% increase, with the full-year FY2025 number at 94.99%, down 1968.0% from a year prior.
  • Return on Capital Employed hit 85.01% in Q2 2025 for KalVista Pharmaceuticals, up from 108.39% in the prior quarter.
  • Over the last five years, Return on Capital Employed for KALV hit a ceiling of 43.76% in Q3 2023 and a floor of 108.39% in Q4 2024.
  • Historically, Return on Capital Employed has averaged 80.84% across 4 years, with a median of 82.32% in 2024.
  • Biggest five-year swings in Return on Capital Employed: plummeted -4444bps in 2024 and later soared 746bps in 2025.
  • Tracing KALV's Return on Capital Employed over 4 years: stood at 75.94% in 2021, then grew by 16bps to 63.95% in 2023, then crashed by -69bps to 108.39% in 2024, then grew by 22bps to 85.01% in 2025.
  • Business Quant data shows Return on Capital Employed for KALV at 85.01% in Q2 2025, 108.39% in Q4 2024, and 79.62% in Q3 2024.